Jesse Dovich, MD, Wins Tesla at 2017 ASCRS Meeting

May 8, 2017: By Market Scope
Jesse Dovich, MD (right), winner of the Tesla at the 2017 ASCRS meeting.

Jesse Dovich, MD (right), winner of the Tesla at the 2017 ASCRS meeting. (Photo by Katie Cannady)

 

Ophthalmologist Jesse Dovich, MD, of Upland, California, was the winner of this year’s drawing for a Tesla electric car at the ASCRS annual meeting in Los Angeles.

The drawing was held May 8 at the ASCRS Exhibit Hall.

Dovich won a 2017 sapphire blue Model S.

He practices at the Pacific Eye Institute and Laser Center, with several locations in California, and is a clinical instructor with the Department of Ophthalmology at Loma Linda University.

In 2015, Thomas Carter, MD, of Ponca City, OK, won the ASCRS’ initial drawing for a 2015 red Tesla Model S at the meeting in San Diego.

In 2016, David Russell Brear, MD, of Culpeper, VA, was the winner of a blue Tesla Model S at the annual meeting in New Orleans.

This year’s drawing was available to conference attendees who obtained specially numbered tickets from exhibitors or ASCRS officials.

Attendees also could gain a ticket by contributing to the ASCRS Foundation or completing the ASCRS clinical survey.

Dovich’s ticket was the first one drawn.

 

A crowd forms May 8 at the Exhibit Hall for the drawing of a Tesla Model S at the 2017 ASCRS meeting in Los Angeles.

A crowd forms May 8 at the Exhibit Hall for the drawing of a Tesla Model S at the 2017 ASCRS meeting in Los Angeles. (Photo by Tony Ingenito)

 

Tesla winner Jesse Dovich after the drawing

Tesla winner Jesse Dovich, MD, after the drawing. (Photo by Katie Cannady)

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US FDA Grants De Novo Request for IDx-DR’s AI Diagnostic System for Diabetic Retinopathy

Allergan Launches TrueTear Intranasal Neurostimulation Device for Dry Eye

Novartis Acquires AveXis, Gene Therapy Platform for $8.7 Billion

Samsung, Biogen Reach Deal with AbbVie over Humira Biosimilar

EyePoint Secures Two US Patents for DEXYCU

SightLife Surgical Rebrands as CorneaGen, Offers New Products

Omidria Earns Listing on VA Formulary, Regains CMS Pass-Through Status

Rayner Launching 600C Monofocal Aspheric IOL in US

LENSAR Laser System Receives 510(k) Clearance for Corneal Pockets, Flaps

EyeGate Completes Enrollment, Receives Milestone Payment for Phase III Study of EGP-437 in Anterior Uveitis

SAV-IOL Seeks $20M in Financing for Active Intraocular Lens Concept with Real-Time Autofocus

AGTC Completes Enrollment for Phase I/II Study of Gene Therapy for X-linked Retinoschisis

Robert Greenberg, MD, PhD, Resigns from Second Sight

US FDA Requires RegeneRx to Conduct Third Phase III Trial for Dry Eye Candidate RGN-259

Stem Cell Implant Yields Positive Results in Phase I/II Study in Dry AMD

Drug Companies Petition Supreme Court to Hear Case Challenging Eye Drop Size

Appeals Court Rules in Favor of Alcon in Suit Brought by Elenza over EAIOLs

ThromboGenics’ THR-137 Demonstrates Safety, Tolerability in Phase I/II Study in DME

GenSight Biologics’ LHON Candidate Improves Eyesight, Fails to Outpace Sham in Phase III Trial

I-MED Pharma’s I-PEN Receives Regulatory Approval in Colombia, Argentina

Coming soon

2018 China Ophthalmic Market Report: An Analysis for 2017 to 2023